What changed in Solventum Corporation's latest annual report
In the year ended 31 Dec 2025, Solventum Corporation's revenue rose 0.9% to USD 8.32bn, from USD 8.25bn; net income rose 224.8% to USD 1.56bn, from USD 479.00m; shareholders' equity rose 70.6% to USD 5.05bn, from USD 2.96bn.
Year ended 31 Dec 2025. Source: 10-K filed 27 Feb 2026, read it on SEC EDGAR.
USD 8.25bn to USD 8.32bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 8.25bn | 8.32bn | Up 0.9% |
| Net income | 479.00m | 1.56bn | Up 224.8% |
| Total assets | 14.46bn | 14.29bn | Down 1.1% |
| Total liabilities | 11.50bn | 9.24bn | Down 19.6% |
| Long-term debt | 7.81bn | 5.04bn | Down 35.5% |
| Cash and cash equivalents | 762.00m | 878.00m | Up 15.2% |
| Shareholders' equity | 2.96bn | 5.05bn | Up 70.6% |
Questions people ask
Did Solventum Corporation's revenue grow last year?
Revenue grew 0.9%, from USD 8.25bn to USD 8.32bn in the year ended 31 Dec 2025.
Is Solventum Corporation profitable?
Yes. Net income was USD 1.56bn in the year ended 31 Dec 2025. The year before: USD 479.00m.
How much cash and debt does Solventum Corporation have?
At its latest year end (31 Dec 2025), Solventum Corporation reported cash and cash equivalents of USD 878.00m and long-term debt of USD 5.04bn.
Where do these numbers come from?
From Solventum Corporation's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Solventum Corporation?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%